Sonoma Pharmaceuticals, Inc. (NASDAQ:SNOA) CFO Robert E. Miller acquired 2,000 shares of the stock in a transaction that occurred on Tuesday, November 21st. The stock was acquired at an average price of $5.03 per share, with a total value of $10,060.00. Following the completion of the transaction, the chief financial officer now directly owns 20,088 shares of the company’s stock, valued at approximately $101,042.64. The acquisition was disclosed in a legal filing with the SEC, which is accessible through this link.
Shares of Sonoma Pharmaceuticals, Inc. (NASDAQ SNOA) traded down $0.10 during midday trading on Monday, hitting $4.66. The stock had a trading volume of 27,858 shares, compared to its average volume of 30,240. The company has a debt-to-equity ratio of 0.01, a quick ratio of 4.56 and a current ratio of 5.37. Sonoma Pharmaceuticals, Inc. has a twelve month low of $4.16 and a twelve month high of $8.25.
Several research firms have recently commented on SNOA. Maxim Group set a $11.00 price target on Sonoma Pharmaceuticals and gave the stock a “buy” rating in a research report on Friday, November 17th. ValuEngine lowered Sonoma Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Friday, September 1st.
An institutional investor recently raised its position in Sonoma Pharmaceuticals stock. Renaissance Technologies LLC increased its stake in Sonoma Pharmaceuticals, Inc. (NASDAQ:SNOA) by 227.6% during the 1st quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 44,622 shares of the company’s stock after acquiring an additional 31,000 shares during the period. Renaissance Technologies LLC owned approximately 1.05% of Sonoma Pharmaceuticals worth $320,000 at the end of the most recent reporting period. Institutional investors and hedge funds own 9.39% of the company’s stock.
TRADEMARK VIOLATION NOTICE: “Sonoma Pharmaceuticals, Inc. (SNOA) CFO Robert E. Miller Buys 2,000 Shares” was originally published by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are accessing this story on another website, it was illegally copied and republished in violation of United States and international copyright laws. The correct version of this story can be viewed at https://www.dispatchtribunal.com/2017/12/11/robert-e-miller-acquires-2000-shares-of-sonoma-pharmaceuticals-inc-snoa-stock.html.
Sonoma Pharmaceuticals Company Profile
Sonoma Pharmaceuticals, Inc, formerly Oculus Innovative Sciences, Inc, is a specialty pharmaceutical company that develops and markets solutions for the treatment of dermatological conditions and advanced tissue care. The Company’s product portfolio consists of dermatology and advanced tissue care products based upon its technologies, such as Microcyn and Lipogrid.
Receive News & Ratings for Sonoma Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sonoma Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.